Open Communication Between Patients and Providers in IBD

In “Open Communication Between Patients and Providers in IBD,” our panel explores the importance of symptom recognition, open patient-provider communication, and early evaluation in inflammatory bowel disease (IBD). The patient panelist reflects on the challenges associated with discussing gastrointestinal symptoms, including urgency, abdominal pain, bowel accidents, and dietary triggers, while emphasizing how important it is for patients to feel comfortable communicating honestly with their healthcare providers. The panel also highlights how patients may normalize or dismiss symptoms over time, delaying evaluation and treatment for conditions such as Crohn’s disease and ulcerative colitis.

Throughout the discussion, expert faculty examine how clinicians distinguish IBD from other gastrointestinal conditions such as irritable bowel syndrome (IBS) and explain why persistent symptoms should be thoroughly evaluated through diagnostic testing and specialist referral when appropriate. The panel discusses how symptom awareness, stool studies, colonoscopy findings, and patient-reported experiences all contribute to identifying active inflammatory disease and guiding treatment decisions.

In addition, the conversation reinforces the value of early treatment intervention and patient engagement throughout the disease journey. The patient panelist shares perspectives on adapting to life with biologic therapy, including experiences with injections, travel, medication adherence, and achieving remission. Expert faculty and the patient panelist emphasize that patients should not feel embarrassed discussing symptoms or asking questions about treatment, monitoring, and side effects. The panel concludes by highlighting how early diagnosis, open communication, and advanced therapies can improve disease control and help patients achieve a better quality of life while living with IBD.

Our next episode, “Navigating Emotional Burdenin IBD,” highlights how patients address the emotional burden of inflammatory bowel disease, including anxiety, depression, fatigue, and fear surrounding symptoms and flares. The panel also discusses how early treatment, biologic therapies, and open communication with healthcare providers can support remission and improve overall quality of life in patients with IBD.